In today’s recent session, 0.65 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.61. Most recently the company’s share price was $47.72, and it changed around $0.47 or 1.00% from the last close, which brings the market valuation of the company to $4.11B. CRSP at last check was trading at a discount to its 52-week high of $91.10, offering almost -90.91% off that amount. The share price’s 52-week low was $43.42, which indicates that the recent value has risen by an impressive 9.01% since then. We note from CRISPR Therapeutics AG’s average daily trading volume that its 10-day average is 2.17 million shares, with the 3-month average coming to 1.22 million.
CRISPR Therapeutics AG stock received a consensus recommendation rating of Hold, based on a mean score of 2.20. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended CRSP as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. CRISPR Therapeutics AG is expected to report earnings per share of -1.24 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
Instantly CRSP has been showing a green trend so far today with a performance of 1.00% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 53.99 on recent trading dayincreased the stock’s daily price by 11.61%. The company’s shares are currently down -23.77% year-to-date, but still down -13.01% over the last five days. On the other hand, CRISPR Therapeutics AG (NASDAQ:CRSP) is -2.45% down in the 30-day period. We can see from the shorts that 18.59 million shares have been sold at a short interest cover period of 17.48 day(s).
The consensus price target as assigned by Wall Street analysts is $89.5, which translates to bulls needing to increase their stock price by 46.68% from its current value. Analyst projections state that CRSP is forecast to be at a low of $52 and a high of $180.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
CRISPR Therapeutics AG share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -13.97 percent over the past six months and at a -168.04% annual growth rate that is well below the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -212.29% in revenue this quarter, and will report an increase of 3.57% in the next quarter. The year-over-year growth rate is expected to be -96.01%, down from the previous year.
Consensus estimates provided by 20 financial analysts predict the company will bring in an average of 7.7M in revenue for the current quarter. 11 analysts expect CRISPR Therapeutics AG to make 10.54M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 201.21M and 504k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -96.17%. Forecasts for the next quarter put sales growth at 1,992.03%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 10.83%. CRISPR Therapeutics AG earnings are expected to increase by -169.91% in 2024, but the outlook is negative -3.70% per year for the next five years.
CRSP Dividends
CRISPR Therapeutics AG’s next quarterly earnings report is expected to be released on 2025-Feb-19.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.71% of CRISPR Therapeutics AG shares, and 72.12% of them are in the hands of institutional investors. The stock currently has a share float of 73.37%. CRISPR Therapeutics AG stock is held by 563.0 institutions, with CAPITAL INTERNATIONAL INVESTORS being the largest institutional investor. By 2024-06-30, it held 9.6159% of the shares, which is about 7.87 million shares worth $424.8 million.
ARK INVESTMENT MANAGEMENT LLC, with 9.5098% or 7.78 million shares worth $420.12 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
